- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | BIOPHYTIS: Biophytis announces its participation to the BIOMED FORUM investor conference | 2 | Euronext | ||
| BIOPHYTIS SA ADR Aktie jetzt für 0€ handeln | |||||
| Mo | Biophytis Announces Its Participation to the BIOMED FORUM Investor Conference | 192 | Newsfile | Paris, France and Cambridge, Massachusetts--(Newsfile Corp. - January 27, 2025) - Biophytis SA (FP: ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specializing in the... ► Artikel lesen | |
| 21.01. | BIOPHYTIS: Biophytis and AskHelpU Sign a Co-Development Agreement in Rare Neuromuscular Diseases in China | 1 | Euronext | ||
| 21.01. | Biophytis and AskHelpU Sign a Co-Development Agreement in Rare Neuromuscular Diseases in China | 212 | Newsfile | Paris, France and Cambridge, Massachusetts--(Newsfile Corp. - January 21, 2025) - Biophytis SA (FP: ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specializing in the... ► Artikel lesen | |
| 14.01. | Biophytis SA - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 14.01. | BIOPHYTIS: Biophytis Enters Exclusive Negotiations with a Chinese Pharmaceutical Company to License BIO101 | 2 | Euronext | ||
| 14.01. | Biophytis Enters Exclusive Negotiations with a Chinese Pharmaceutical Company to License BIO101 | 249 | Newsfile | Paris, France and Cambridge, Massachusetts--(Newsfile Corp. - January 14, 2025) - Biophytis SA (OTC Pink: BPTSY) (FP: ALBPS) ("Biophytis" or the "Company"), a clinical-stage biotechnology company specializing... ► Artikel lesen | |
| 08.01. | BIOPHYTIS: Biophytis Announces New Cash Contribution and Debt Conversion up to €8.6 million to Finance the Obesity Program | 9 | Euronext | ||
| 06.01. | Biophytis SA - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 06.01. | BIOPHYTIS: Biophytis announces temporary suspension of the listing of its shares and share warrants prior to the completion of a refinancing transaction | 6 | Euronext | ||
| 24.12.24 | BIOPHYTIS: Biophytis Will Be In San Franscico During The 2025 JP Morgan Healthcare Conference | 4 | Euronext | ||
| 23.12.24 | BIOPHYTIS: Biophytis showcased the OBA program in obesity at the 17th SCWD international congress | 4 | Euronext | ||
| 02.12.24 | BIOPHYTIS: Biophytis participates in the 17th SCWD Congress and hosts an Obesity Investor Call | 4 | Euronext | ||
| 11.10.24 | Biophytis GAAP EPS of -€9.48 | 4 | Seeking Alpha | ||
| 30.09.24 | Biophytis Publishes First-Half Financial Results and Provides an Update on its Business Activities | 452 | ACCESS Newswire | PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / September 30, 2024 / Biophytis SA (Euronext Growth Paris:ALBPS) ("Biophytis" or the "Company"), a clinical-stage biotechnology company focused on developing... ► Artikel lesen | |
| 30.09.24 | BIOPHYTIS: Biophytis Publishes First-Half Financial Results and Provides an Update on its Business Activities | 3 | Euronext | ||
| 30.09.24 | Biophytis SA - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 22.07.24 | Biophytis Deploys its Partnership Strategy and Signs Two Contracts with Local Agents in Asia | 468 | ACCESS Newswire | PARIS, FRANCE AND CAMBRIDGE, MA / ACCESSWIRE / July 22, 2024 / Biophytis SA (Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specializing in the... ► Artikel lesen | |
| 11.07.24 | Biophytis Obtains IND Approval from the FDA to Start its Phase 2 OBA Study in Obesity | 329 | ACCESS Newswire | PARIS, FRANCE AND CAMBRIDGE, MA / ACCESSWIRE / July 11, 2024 / Biophytis SA (Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in the development... ► Artikel lesen | |
| 01.07.24 | Biophytis Presented its Phase 2-3 COVA Study Results in Severe Forms of Covid-19 at the WCID in Paris | 385 | ACCESS Newswire | PARIS, FRANCE AND CAMBRIDGE, MA / ACCESSWIRE / July 1, 2024 / Biophytis SA (Euronext Growth Paris: ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in the development... ► Artikel lesen |
Seite:
1 2 3 Weiter >>
42 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CUREVAC | 3,704 | -0,48 % | CureVac Aktie testet 200-Tage-Linie: Kommt neuer Kursschub? | Die CureVac Aktie hat sich seit den beiden Baissetiefs aus dem Jahr 2024 bei 2,22/2,37 Dollar zuletzt wieder spürbar erholt. Die jüngste Rallye startete bei 2,37 Dollar und führte den Kurs am 7. Januar... ► Artikel lesen | |
| VALNEVA | 2,510 | +5,02 % | Valneva plant Phase-3-Studie für Chikungunya-Impfstoff bei Kindern | Valneva SE hat Ergebnisse aus der Phase-2-Studie ihres Chikungunya-Impfstoffs IXCHIQ bei Kindern im Alter von ein bis elf Jahren veröffentlicht. In der Studie, die von der Coalition for Epidemic Preparedness... ► Artikel lesen | |
| BIOFRONTERA | 2,385 | -4,02 % | PTA-News: Biofrontera AG: Biofrontera berichtet über die Ergebnisse der ersten neun Monate des Jahres 2024 | DJ PTA-News: Biofrontera AG: BIOFRONTERA BERICHTET ÜBER DIE ERGEBNISSE DER ERSTEN NEUN MONATE DES JAHRES 2024
Unternehmensmitteilung für den Kapitalmarkt
Leverkusen (pta/29.11.2024/17:00)... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 0,885 | +2,43 % | Palatin bereitet sich auf Adipositas-Behandlungsstudien im Jahr 2025 vor | ||
| AAP IMPLANTATE | 1,840 | 0,00 % | EQS-News: aap Implantate AG: Deutliche Fortschritte in allen operativen Bereichen; stabiles viertes Quartal führt zu 12.2 Mio. EUR Jahres-Umsatz (+6%) | EQS-News: aap Implantate AG
/ Schlagwort(e): Vertriebsergebnis
Deutliche Fortschritte in allen operativen Bereichen; stabiles viertes Quartal führt zu 12.2 Mio. EUR Jahres-Umsatz... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 2,000 | +2,04 % | Pre-market Movers: Loop Industries, Repare Therapeutics, Candel Therapeutics, Inovio Pharmaceuticals, iSpecimen |
OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 07.35 A.M. ET).In the Green Loop Industries, Inc. (LOOP) is up over 56% at $1.93.
iSpecimen... ► Artikel lesen | |
| MAINZ BIOMED | 5,695 | -100,00 % | EQS-News: Mainz BioMed N.V.: Mainz Biomed N.V. qualifiziert sich wieder für die Notierung am Nasdaq Capital Market | Emittent / Herausgeber: Mainz BioMed N.V.
/ Schlagwort(e): Sonstiges
Mainz Biomed N.V. qualifiziert sich wieder für die Notierung am Nasdaq Capital Market
27.01.2025 /... ► Artikel lesen | |
| SANGAMO THERAPEUTICS | 1,155 | +5,93 % | Expert Outlook: Sangamo Therapeutics Through The Eyes Of 11 Analysts | ||
| INFLARX | 2,204 | +1,94 % | Inflarx-Zulassung: Hoffnung über COVID-19 hinaus | ||
| VIKING THERAPEUTICS | 32,580 | +1,53 % | Viking Therapeutics Stock Before Q4 Earnings: To Buy or Not to Buy? | ||
| INTELLIA THERAPEUTICS | 10,220 | +5,19 % | How Is The Market Feeling About Intellia Therapeutics? | ||
| SCORPIUS | 0,289 | 0,00 % | XFRA 1HB0: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILSCORP.HLDGS.NEW... ► Artikel lesen | |
| EDITAS MEDICINE | 1,349 | +4,37 % | Editas Medicine, Inc.: Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities | Achieved in vivo preclinical proof of concept of editing hematopoietic stem cells in non-human primates as a key step toward developing a novel in vivo treatment for sickle cell disease and beta thalassemia... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 110,00 | -0,86 % | Sarepta Reports Positive Phase 3 EMBARK Data For Elevidys In Duchenne Muscular Dystrophy | WASHINGTON (dpa-AFX) - Sarepta Therapeutics, Inc. (SRPT) Monday reported positive topline results from Part 2 of the Phase 3 study, dubbed EMBARK, of its gene therapy Elevidys approved for the... ► Artikel lesen | |
| REDHILL BIOPHARMA | 6,100 | 0,00 % | RedHill Biopharma Ltd.: New Peer-Reviewed Publication of Opaganib Phase 2/3 Data Shows 62% Reduction in COVID-19 Mortality | Data, from a post hoc analysis of the randomized, placebo-controlled, double-blind phase 2/3 study of oral opaganib in COVID-19 pneumonia, showing a 62% reduction in mortality and a 21% improvement... ► Artikel lesen |
Das Unternehmen BIOPHYTIS SA ADR kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,224 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOPHYTIS SA ADR finden Sie auf Wallstreet Online.
